{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:55:51Z","timestamp":1787241351572,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sham Kakar","award":["NAH R25GM133328"],"award-info":[{"award-number":["NAH R25GM133328"]}]},{"name":"Sham Kakar","award":["NAH R25GM133328"],"award-info":[{"award-number":["NAH R25GM133328"]}]},{"name":"Sham Kakar","award":["NAH R25GM133328"],"award-info":[{"award-number":["NAH R25GM133328"]}]},{"name":"Sham Kakar","award":["NAH R25GM133328"],"award-info":[{"award-number":["NAH R25GM133328"]}]},{"name":"Sham Kakar","award":["NAH R25GM133328"],"award-info":[{"award-number":["NAH R25GM133328"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cachexia a multifactorial syndrome is a common sequala in patients with cancer. It varies from 42 to 80% depending upon the oncological stage and is directly responsible for 30% of deaths in these patients. Previous research from our laboratory demonstrated that peritoneal ovarian cancer generated in NSG mice resulted in skeletal and cardiac muscle atrophy - leading to loss of skeletal muscle mass and strength, and cardiac dysfunction (cachexia). Treatment of mice bearing i.p. tumors with withaferin A (WFA) showed reversal of skeletal muscle and cardiac cachexia. The present study is focused on determining effects of peritoneal ovarian tumors on kidney damage and effects of WFA treatment on ameliorating kidney damage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We generated intraperitoneal ovarian cancer by injecting female NSG mice with ovarian cancer cell line (A2780). After one week of injecting cancer cells, mice were treated with WFA (4\u00a0mg\/kg) every third day, for three weeks. After 4 weeks of injection of cancer cells, the mice were sacrificed and various tissues including kidney and blood were collected, snap-frozen in liquid nitrogen, and stored at -80\n                      <jats:sup>0<\/jats:sup>\n                      C. The presence of kidney biomarker creatinine, was measured in the plasma by an ELISA. The mRNA was isolated from mouse kidneys and was used to examine the expression levels of signaling proteins, inflammatory cytokines, and genes responsible for inducing cachexia (IL-1\u03b2, IL-6, TNF-\u03b1, TGF-\u03b2, GDF-15, and MYD88).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our results showed a significant increase in levels of expression of inflammatory cytokine IL-1 \u03b2 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), IL-6 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), TNF-\u03b1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and other related genes including TRAF6 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), MYD88 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), and GDF-15 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) in tumor-bearing mice compared to controls. Treatment of mice bearing tumors with WFA attenuated the increase in expression of each gene. In addition, our results showed a significant increase in creatinine levels in circulation in tumor-bearing mice compared to control mice. Treatment of tumor-bearing mice with WFA resulted in a significant decrease in plasma creatinine levels compared to tumor-bearing mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results conclude that ovarian tumors in NSG mice caused kidney damage and renal dysfunction, which was effectively ameliorated by WFA treatment, suggesting a protective effect of WFA on kidney injury induced by ovarian cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-024-01519-9","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T07:01:51Z","timestamp":1728630111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Withaferin A ameliorates ovarian cancer-induced renal damage through the regulation of expression of inflammatory cytokines"],"prefix":"10.1186","volume":"17","author":[{"given":"Kusum","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasa","family":"Vemuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Kratholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Rane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham S.","family":"Kakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"issue":"5","key":"1519_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1519_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KC Fearon","year":"2012","unstructured":"Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metabol. 2012;16(2):153\u201366. https:\/\/doi.org\/10.1016\/j.cmet.2012.06.011.","journal-title":"Cell Metabol"},{"issue":"10","key":"1519_CR3","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.biocel.2013.05.032","volume":"45","author":"N Johns","year":"2013","unstructured":"Johns N, Stephens NA, Fearon KC. Muscle wasting in cancer. Int J Biochem Cell Biol. 2013;45(10):2215\u201329. https:\/\/doi.org\/10.1016\/j.biocel.2013.05.032.","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"1519_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/s1357-2725(02)00251-0","volume":"35","author":"JM Argil\u00e9s","year":"2003","unstructured":"Argil\u00e9s JM, Moore-Carrasco R, Fuster G, Busquets S, L\u00f3pez-Soriano FJ. Cancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol. 2003;35(4):405\u20139. https:\/\/doi.org\/10.1016\/s1357-2725(02)00251-0.","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"1519_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1152\/japplphysiol.00196.2023","volume":"135","author":"AR Cabrera","year":"2023","unstructured":"Cabrera AR, Deaver JW, Lim S, Morena da Silva F, Schrems ER, Saling LW, Tsitkanou S, Rosa-Caldwell ME, Wiggs MP, Washington TA, Greene NP. Females display relatively preserved muscle quality compared with males during the onset and early stages of C26-induced cancer cachexia. J Appl Physiol (Bethesda Md: 1985). 2023;135(3):655\u201372. https:\/\/doi.org\/10.1152\/japplphysiol.00196.2023.","journal-title":"J Appl Physiol (Bethesda Md: 1985)"},{"issue":"6","key":"1519_CR6","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/cells11060990","volume":"11","author":"S Saha","year":"2022","unstructured":"Saha S, Singh PK, Roy P, Kakar SS. Cardiac Cachexia: unaddressed aspect in Cancer patients. Cells. 2022;11(6):990. https:\/\/doi.org\/10.3390\/cells11060990.","journal-title":"Cells"},{"issue":"7","key":"1519_CR7","doi-asserted-by":"publisher","first-page":"e0236680","DOI":"10.1371\/journal.pone.0236680","volume":"15","author":"NQ Kelm","year":"2020","unstructured":"Kelm NQ, Straughn AR, Kakar SS. Withaferin a attenuates ovarian cancer-induced cardiac cachexia. PLoS ONE. 2020;15(7):e0236680. https:\/\/doi.org\/10.1371\/journal.pone.0236680.","journal-title":"PLoS ONE"},{"key":"1519_CR8","doi-asserted-by":"publisher","first-page":"636498","DOI":"10.3389\/fcell.2021.636498","volume":"9","author":"AR Straughn","year":"2021","unstructured":"Straughn AR, Kelm NQ, Kakar SS. Withaferin A and Ovarian Cancer Antagonistically regulate skeletal muscle Mass. Front cell Dev Biology. 2021;9:636498. https:\/\/doi.org\/10.3389\/fcell.2021.636498.","journal-title":"Front cell Dev Biology"},{"issue":"2","key":"1519_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10456-004-1026-3","volume":"7","author":"R Mohan","year":"2004","unstructured":"Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ, Ruiz A, Zhang L, Hanson AD, Conner BP, Rougas J, Pribluda VS. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis. 2004;7(2):115\u201322. https:\/\/doi.org\/10.1007\/s10456-004-1026-3.","journal-title":"Angiogenesis"},{"issue":"4","key":"1519_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1742-7843.2004.pto940405.x","volume":"94","author":"I Mohanty","year":"2004","unstructured":"Mohanty I, Arya DS, Dinda A, Talwar KK, Joshi S, Gupta SK. Mechanisms of cardioprotective effect of Withania somnifera in experimentally induced myocardial infarction. Basic Clin Pharmacol Toxicol. 2004;94(4):184\u201390. https:\/\/doi.org\/10.1111\/j.1742-7843.2004.pto940405.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1\u20132","key":"1519_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1023\/b:mcbi.0000026051.16803.03","volume":"260","author":"SK Gupta","year":"2004","unstructured":"Gupta SK, Mohanty I, Talwar KK, Dinda A, Joshi S, Bansal P, Saxena A, Arya DS. Cardioprotection from ischemia and reperfusion injury by Withania somnifera: a hemodynamic, biochemical and histopathological assessment. Mol Cell Biochem. 2004;260(1\u20132):39\u201347. https:\/\/doi.org\/10.1023\/b:mcbi.0000026051.16803.03.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"1519_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13048-019-0586-1","volume":"12","author":"AR Straughn","year":"2019","unstructured":"Straughn AR, Kakar SS. Withaferin a ameliorates ovarian cancer-induced cachexia and proinflammatory signaling. J Ovarian Res. 2019;12(1):115. https:\/\/doi.org\/10.1186\/s13048-019-0586-1.","journal-title":"J Ovarian Res"},{"issue":"1","key":"1519_CR13","doi-asserted-by":"publisher","first-page":"bqad176","DOI":"10.1210\/endocr\/bqad176","volume":"165","author":"CS Callaway","year":"2023","unstructured":"Callaway CS, Mouchantat LM, Bitler BG, Bonetto A. Mechanisms of Ovarian Cancer-Associated Cachexia. Endocrinology. 2023;165(1):bqad176. https:\/\/doi.org\/10.1210\/endocr\/bqad176.","journal-title":"Endocrinology"},{"issue":"4","key":"1519_CR14","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/nuf.12623","volume":"56","author":"IM Hweidi","year":"2021","unstructured":"Hweidi IM, Al-Omari AK, Rababa MJ, Al-Obeisat SM, Hayajneh AA. Cardiac cachexia among patients with chronic heart failure: a systematic review. Nurs Forum. 2021;56(4):916\u201324. https:\/\/doi.org\/10.1111\/nuf.12623.","journal-title":"Nurs Forum"},{"issue":"7\u20138","key":"1519_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00011-022-01586-y","volume":"71","author":"R Nogueira-Ferreira","year":"2022","unstructured":"Nogueira-Ferreira R, Sousa-Nunes F, Leite-Moreira A, Moreira-Costa L, Vitorino R, Lara Santos L, Moreira-Gon\u00e7alves D, Ferreira R. Cancer- and cardiac-induced cachexia: same fate through different inflammatory mediators? Inflamm Research: Official J Eur Histamine Res Soc \u2026 et al ]. 2022;71(7\u20138):771\u201383. https:\/\/doi.org\/10.1007\/s00011-022-01586-y.","journal-title":"Inflamm Research: Official J Eur Histamine Res Soc \u2026 et al ]"},{"issue":"17","key":"1519_CR16","doi-asserted-by":"publisher","first-page":"17706","DOI":"10.1002\/cam4.6388","volume":"12","author":"L Tichy","year":"2023","unstructured":"Tichy L, Parry TL. The pathophysiology of cancer-mediated cardiac cachexia and novel treatment strategies: a narrative review. Cancer Med. 2023;12(17):17706\u201317. https:\/\/doi.org\/10.1002\/cam4.6388.","journal-title":"Cancer Med"},{"issue":"9","key":"1519_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/cells13090783","volume":"13","author":"V Vemuri","year":"2024","unstructured":"Vemuri V, Kratholm N, Nagarajan D, Cathey D, Abdelbaset-Ismail A, Tan Y, Straughn A, Cai L, Huang J, Kakar SS. Withaferin A as a potential therapeutic target for the treatment of angiotensin II-Induced Cardiac Cachexia. Cells. 2024;13(9):783. https:\/\/doi.org\/10.3390\/cells13090783.","journal-title":"Cells"},{"issue":"1","key":"1519_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1053\/j.ackd.2017.09.003","volume":"25","author":"P Bjornstad","year":"2018","unstructured":"Bjornstad P, Karger AB, Maahs DM. Measured GFR in routine clinical practice-the Promise of dried blood spots. Adv Chronic Kidney Dis. 2018;25(1):76\u201383. https:\/\/doi.org\/10.1053\/j.ackd.2017.09.003.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"9","key":"1519_CR19","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1681\/ASN.2016020177","volume":"27","author":"HJ Anders","year":"2016","unstructured":"Anders HJ. Of inflammasomes and alarmins: IL-1\u03b2 and IL-1\u03b1 in kidney disease. J Am Soc Nephrology: JASN. 2016;27(9):2564\u201375. https:\/\/doi.org\/10.1681\/ASN.2016020177.","journal-title":"J Am Soc Nephrology: JASN"},{"issue":"6372","key":"1519_CR20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/356768a0","volume":"356","author":"NA Thornberry","year":"1992","unstructured":"Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992;356(6372):768\u201374. https:\/\/doi.org\/10.1038\/356768a0.","journal-title":"Nature"},{"key":"1519_CR21","doi-asserted-by":"publisher","unstructured":"Lemos DR, Mcmurdo M, Karaca G, Wilflingseder J, Leaf IA, Gupta N, Miyoshi T, Susa K, Johnson BG, Soliman K, Wang G, Morizane R, Bonventre JV, Duffield JS. Interleukin-1\u03b2 activates a MYC-Dependent metabolic switch in kidney stromal cells necessary for Progressive Tubulointerstitial Fibrosis. Ovid Technologies (Wolters Kluwer Health; 2018. https:\/\/doi.org\/10.1681\/asn.2017121283.","DOI":"10.1681\/asn.2017121283"},{"issue":"12","key":"1519_CR22","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1002\/art.24959","volume":"60","author":"M Guma","year":"2009","unstructured":"Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M. Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum. 2009;60(12):3642\u201350. https:\/\/doi.org\/10.1002\/art.24959.","journal-title":"Arthritis Rheum"},{"key":"1519_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01107","author":"T Dainichi","year":"2019","unstructured":"Dainichi T, Matsumoto R, Mostafa A, Kabashima K. Immune Control by TRAF6-Mediated pathways of epithelial cells in the EIME (epithelial Immune Microenvironment). Front Media SA. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.01107.","journal-title":"Front Media SA"},{"issue":"10","key":"1519_CR24","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1152\/ajprenal.00557.2012","volume":"304","author":"VD Ramseyer","year":"2013","unstructured":"Ramseyer VD, Garvin JL. Tumor necrosis factor-\u03b1: regulation of renal function and blood pressure. Am J Physiol - Ren Physiol. 2013;304(10):1231\u201342. https:\/\/doi.org\/10.1152\/ajprenal.00557.2012.","journal-title":"Am J Physiol - Ren Physiol"},{"issue":"4","key":"1519_CR25","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/sj.cdd.4402304","volume":"15","author":"K Yoon","year":"2008","unstructured":"Yoon K, Jung EJ, Lee SR, Kim J, Choi Y, Lee SY. TRAF6 deficiency promotes TNF-induced cell death through inactivation of GSK3\u03b2. Cell Death Differ. 2008;15(4):730\u20138. https:\/\/doi.org\/10.1038\/sj.cdd.4402304.","journal-title":"Cell Death Differ"},{"issue":"2","key":"1519_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.krcp.2012.04.322","volume":"31","author":"SI Kim","year":"2012","unstructured":"Kim SI, Choi ME. TGF-\u03b2-activated kinase-1: new insights into the mechanism of TGF-\u03b2 signaling and kidney disease. Kidney Res Clin Pract. 2012;31(2):94\u2013105. https:\/\/doi.org\/10.1016\/j.krcp.2012.04.322.","journal-title":"Kidney Res Clin Pract"},{"key":"1519_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00123","author":"Y Gu","year":"2020","unstructured":"Gu Y, Liu X, Huang X, Yu X, Lan H. Diverse role of TGF-\u03b2 in kidney disease. Front Media SA. 2020. https:\/\/doi.org\/10.3389\/fcell.2020.00123.","journal-title":"Front Media SA"},{"key":"1519_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-3-7091-6301-6_18","volume":"60","author":"J Strelau","year":"2000","unstructured":"Strelau J, B\u00f6ttner M, Lingor P, Suter-Crazzolara C, Galter D, Jaszai J, Sullivan A, Schober A, Krieglstein K, Unsicker K. GDF-15\/MIC-1 a novel member of the TGF-beta superfamily. J Neural Transm Suppl. 2000;60:273\u20136. https:\/\/doi.org\/10.1007\/978-3-7091-6301-6_18.","journal-title":"J Neural Transm Suppl"},{"issue":"4","key":"1519_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/jcsm.12077","volume":"7","author":"L Lerner","year":"2016","unstructured":"Lerner L, Tao J, Liu Q, Nicoletti R, Feng B, Krieger B, Mazsa E, Siddiquee Z, Wang R, Huang L, Shen L, Lin J, Vigano A, Chiu MI, Weng Z, Winston W, Weiler S, Gyuris J. MAP3K11\/GDF15 axis is a critical driver of cancer cachexia. J cachexia Sarcopenia Muscle. 2016;7(4):467\u201382. https:\/\/doi.org\/10.1002\/jcsm.12077.","journal-title":"J cachexia Sarcopenia Muscle"},{"issue":"19","key":"1519_CR30","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.3390\/cancers13194842","volume":"13","author":"H Suzuki","year":"2021","unstructured":"Suzuki H, Mitsunaga S, Ikeda M, Aoyama T, Yoshizawa K, Yoshimatsu H, Kawai N, Masuda M, Miura T, Ochiai A. Clinical and tumor characteristics of patients with high serum levels of growth differentiation factor 15 in Advanced Pancreatic Cancer. Cancers. 2021;13(19):4842. https:\/\/doi.org\/10.3390\/cancers13194842.","journal-title":"Cancers"},{"issue":"4","key":"1519_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/jcsm.12033","volume":"6","author":"L Lerner","year":"2015","unstructured":"Lerner L, Hayes TG, Tao N, Krieger B, Feng B, Wu Z, Nicoletti R, Chiu MI, Gyuris J, Garcia JM. Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients. J cachexia Sarcopenia Muscle. 2015;6(4):317\u201324. https:\/\/doi.org\/10.1002\/jcsm.12033.","journal-title":"J cachexia Sarcopenia Muscle"},{"issue":"11","key":"1519_CR32","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/nm1677","volume":"13","author":"H Johnen","year":"2007","unstructured":"Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, Bauskin AR, Wu L, Pankhurst G, Jiang L, Junankar S, Hunter M, Fairlie WD, Lee NJ, Enriquez RF, Baldock PA, Corey E, Apple FS, Murakami MM, Lin EJ, Wang C, Breit SN. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med. 2007;13(11):1333\u201340. https:\/\/doi.org\/10.1038\/nm1677.","journal-title":"Nat Med"},{"key":"1519_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-physiol-020518-114605","volume":"81","author":"WR Zhang","year":"2019","unstructured":"Zhang WR, Parikh CR. Biomarkers of Acute and chronic kidney disease. Annu Rev Physiol. 2019;81:309\u201333. https:\/\/doi.org\/10.1146\/annurev-physiol-020518-114605.","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"1519_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KCH Fearon","year":"2012","unstructured":"Fearon KCH, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metabol. 2012;16(2):153\u201366. https:\/\/doi.org\/10.1016\/j.cmet.2012.06.011.","journal-title":"Cell Metabol"},{"issue":"1","key":"1519_CR35","doi-asserted-by":"publisher","first-page":"111947","DOI":"10.1016\/j.celrep.2022.111947","volume":"42","author":"JY Kim-Muller","year":"2023","unstructured":"Kim-Muller JY, Song L, LaCarubba Paulhus B, Pashos E, Li X, Rinaldi A, Joaquim S, Stansfield JC, Zhang J, Robertson A, Pang J, Opsahl A, Boucher M, Breen D, Hales K, Sheikh A, Wu Z, Zhang BB. GDF15 neutralization restores muscle function and physical performance in a mouse model of cancer cachexia. Cell Rep. 2023;42(1):111947. https:\/\/doi.org\/10.1016\/j.celrep.2022.111947.","journal-title":"Cell Rep"},{"issue":"7","key":"1519_CR36","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1681\/ASN.2016080919","volume":"28","author":"V Nair","year":"2017","unstructured":"Nair V, Robinson-Cohen C, Smith MR, Bellovich KA, Bhat ZY, Bobadilla M, Brosius F, de Boer IH, Essioux L, Formentini I, Gadegbeku CA, Gipson D, Hawkins J, Himmelfarb J, Kestenbaum B, Kretzler M, Magnone MC, Perumal K, Steigerwalt S, Ju W, Bansal N. Growth differentiation Factor-15 and risk of CKD progression. J Am Soc Nephrology: JASN. 2017;28(7):2233\u201340. https:\/\/doi.org\/10.1681\/ASN.2016080919.","journal-title":"J Am Soc Nephrology: JASN"},{"key":"1519_CR37","doi-asserted-by":"publisher","unstructured":"Deguine J, Barton GM. (2014). MyD88: a central player in innate immune signaling. F1000 Prime Reports, 6, 97. https:\/\/doi.org\/10.12703\/P6-97","DOI":"10.12703\/P6-97"},{"issue":"1","key":"1519_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, Zeng C, Zhou T, Zhang J. NF-\u03baB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Therapy. 2024;9(1):53. https:\/\/doi.org\/10.1038\/s41392-024-01757-9.","journal-title":"Signal Transduct Target Therapy"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-024-01519-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-024-01519-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-024-01519-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T18:03:39Z","timestamp":1728669819000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-024-01519-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1519"],"URL":"https:\/\/doi.org\/10.1186\/s13048-024-01519-9","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}